Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

OnabotulinumtoxinA injections are safe and well-tolerated in children and adolescents, with no patients reporting severe adverse events across all published studies and common adverse events predominantly comprising minor injection-site reactions.

OnabotulinumtoxinA Appears to be Safe and Effective in Pediatric Chronic Migraine, With More Controlled Studies Needed

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 24, 2024. 

NeurologyLive® Friday 5 — January 24, 2024

Videos

The chief executive officer and cofounder of Amprion discussed the integration process of a novel a-synuclein seed amplification assay used to distinguish seeds from Lewy bodies and glilal cytoplasmic inclusions. [WATCH TIME: 2 minutes]

Feasibility and Scalability of Amprion’s Assay for Synucleinopathy Diagnosis: Russ Lebovitz, MD, PhD

In a recent survey, key factors associated with perceived support included knowing someone who had the same diagnosis of their sleep disorder, younger age, and marital status. 

Survey Highlights Patients’ Need for Support in Adapting to Life in Narcolepsy or Idiopathic Hypersomnia

Director of programs at the Child Neurology Foundation.

Jessica Nickrand, PhD, and Allyson Eyermann from the Child Neurology Foundation emphasized the importance of multidisciplinary collaboration for children with epilepsy and their families.

Insights From the Child Neurology Foundation: Enhancing Pediatric Epilepsy Care Through Holistic Collaboration

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Depobam Samanta, MD, MS, FAAP, FAES. [LISTEN TIME: 25 minutes]

Episode 133: Clinical Guidance on Neuromodulation for Lennox-Gastaut Syndrome

The medical director of the Arkansas Children’s Comprehensive Epilepsy Program provided commentary on patient selection and personalized treatment approaches when using neuromodulation devices for Lennox-Gastaut syndrome. [WATCH TIME: 3 minutes]

Personalizing Neuromodulation and Tailoring Approaches for Lennox-Gastaut Syndrome: Depobam Samanta, MD, MS, FAAP, FAES

Leah Blank, MD, an assistant professor of neurology, population health, science, and policy at the Icahn School of Medicine provided commentary on some of the experience and positive movement from the 2024 American Epilepsy Society Annual Meeting.

Insights From AES 2024: Advancements and Challenges in Epilepsy Care

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AES 2024

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1.125rem

Clinical

 Parkinson disease Disease Spotlight page gives readers key updates and detailed coverage on the most recent expert conversations and data presentations relevant to the treatment of the movement disorder.

Stuart Isaacson, MD, Rajesh Pahwa, MD, and Jennifer Goldman, MD discuss optimizing PD treatment with levodopa and adjunct therapies, addressing patient and pharmacologic challenges, coordinating care, and anticipating the impact of emerging therapies and upcoming Medicare Part D changes.

Medcast Podcasts

Optimizing Parkinson's disease (PD) treatment involves leveraging levodopa and adjunct therapies to address both patient-specific and pharmacologic challenges. Effective management requires coordinated care among healthcare providers to ensure comprehensive treatment strategies. Anticipating the impact of emerging therapies and upcoming changes in Medicare Part D is crucial for adapting treatment plans. These changes may influence drug accessibility and affordability, necessitating proactive adjustments in therapeutic approaches. Understanding these dynamics is essential for improving patient outcomes and maintaining the efficacy of PD management strategies.

Stuart Isaacson, MD, Rajesh Pahwa, MD, and Jennifer Goldman, MD discuss optimizing PD treatment with levodopa and adjunct therapies, addressing patient and pharmacologic challenges, coordinating care, and anticipating the impact of emerging therapies and upcoming Medicare Part D changes.

Multisymptomatic Care in Parkinson's Disease

 is now live! Scroll down to listen, and make sure to subscribe on your favorite streaming service.

 features Dr. Anne Marie Morse, DO, a neurologist with special qualifications in child neurology and a sleep medicine specialist, best known for putting the DAMM in 

 and for always looking for digestible, actionable patient-directed sleep tips, tricks and tools to achieve optimal outcomes. Dr. Morse has joined forces with Brandon Hedgecock, DDS, D-ABDSM, a dentist and founder of Hedgecock Dental and 

; and Matthew Allard, AKA the "Sleep Connector," an experienced sleep professional with 20 years of experience helping others sleep and breathe better nightly, to break down the barriers between dentistry and medicine to develop educational content that considers the whole person and illustrate how sleep relates to lifestyle, wellness, and culture.

Sleeping Around the Podcast realized they had more to give and are a partner with 

Sleeping Around the Podcast × NeurologyLive

 for neurology-focused sleep content to allow any neurology stakeholder to add to their knowledge bank and skillset on how to use sleep as the diagnostic, prognostic, and therapeutic neurology tool it is designed to be.

 – Connection between PD and sleep disorders

 – Overview of study assessing biomarker for EDS in Parkinson disease

 – Role of neurofilament light chain in PD

– Patient demographics and differences of NfL increases 

. Check out the links below to subscribe on your preferred podcast platform.

DAMM Good Sleep

Sleeping Around the Podcast × NeurologyLive brings you a clinical overview of a newly published study highlighting extracellular vesicle-associated miRNA features that could be diagnostically informative of RBD in patients with Parkinson disease.

Sleeping Around the Podcast × NeurologyLive: Candidate Biomarkers to Detect REM Sleep Behavior Disorder in Parkinson Disease

Watch the video version of this episode here. 

Dyskinesia: Importance of Giving Patients More Good “On- Time" in Parkinson’s Disease

Drs Isaacson, Pahwa, and Gupta discuss the management of dyskinesia and providing good ON time in Parkinson’s disease, sharing practical tips for early identification and treatment of dyskinesia, as well as their experience with current treatments.

 – Sleep disturbances as major feature of PD

 – Parkinson-related pathological changes

Sleeping Around the Podcast × NeurologyLive brings you a scientific overview of the crossover between Parkinson disease and sleep disorders. 

Sleeping Around the Podcast × NeurologyLive: Parkinson Disease Awareness Month

To watch the full video episode, follow this link. 

Widening the Therapeutic Window in the Management of Parkinson’s Disease

Expert neurologists discuss strategies to widen the therapeutic window of Parkinson’s disease and options available to treat dyskinesia, providing better control of Parkinson’s disease.

 to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 93, "Caring for Women With Parkinson Disease," features an exclusive interview with 

, an assistant professor of neurology and director of the Parkinson’s Disease & Movement Disorder Program at Global Neurosciences Institute, who spoke with us about the current landscape of care for women with Parkinson disease (PD), how the approach to their care can differ from men, the major gaps around education and treatment for these women, and much more.

, a streaming channel from MJH Life Sciences

. Check out new content and shows every day, only at

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

FDA Issues Complete Response Letter to Amneal for Parkinson Agent IPX203

FDA Grants Traditional Approval to Lecanemab as Therapy for Early-Stage Alzheimer Disease

Medicare Expands Coverage for Fully Approved Alzheimer Agent Lecanemab

FDA Approves Image Guided Programming Software for Vercise Deep Brain Stimulation Systems

 – The presentation of Parkinson disease for women

 – Nonmotor symptoms that can create challenges  for diagnosis

 – OFF episodes and dyskinesia in women vs men

 – Being attentive to patient needs in treatment

 – The daily impact of Parkinson disease

 – Encouraging women with Parkinson to participate in trials

– Conversations in areas of limited knowledge

 to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Hoping to listen on your favorite podcast app? See below:

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jill Farmer, DO, MPH. [LISTEN TIME: 28 minutes]

Episode 93: Caring for Women With Parkinson Disease

 podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 81, "Widening the Therapeutic Window in Parkinson Disease," features an exclusive interview with Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida. He spoke about the current state of therapeutics in Parkinson disease, some of the lingering challenges in day-to-day management, the promise of novel agents in development such as IPX203, and more.

This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. 

Neurelis Files IND for Potentially First Therapy to Treat Cerebral Cavernous Malformations

CDC and FDA Announce Stroke Safety Concern Related to Pfizer-BioNTech Bivalent COVID-19 Vaccine

FDA Hands Eli Lilly Complete Response Letter for Donanemab After Lack of Long-Term Data

FDA Clears Trial Hold on Late-Onset Pompe Disease Gene Therapy AT845

Proclaim XR Spinal Cord Stimulation Wins Approval for Painful Diabetic Peripheral Neuropathy

 – Lingering unmet needs in Parkinson disease management

 – The advances in identifying therapeutic targets in PD

 – Bridging the gap to more effective long-term treatment

 – Overview of IPX203 and its potential to treat PD

 – Safety profile of IPX203 in clinical development

 – The importance of addressing dose-wearing off

 podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Robert A. Hauser, MD, MBA. [LISTEN TIME: 20 minutes]

Episode 81: Widening the Therapeutic Window in Parkinson Disease

Episode 78, "A Virtual Reality Platform for Parkison Disease," features an exclusive interview with Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic. He joined the show to discuss the complexities that come with understanding early signs of PD, and how the newly designed Cleveland Clinic Virtual Reality Shopping (CC-VRS) platform works towards that, among other topics.

. Check out new episodes of a variety of shows, airing every single day, only on

International Committee Proposes MS Disease Progression Framework Driven by Pathophysiological Mechanisms, Not Clinical Phenotype

Anti-Amyloid-ß Oligomer Antibody ACU193 Gains FDA Fast Track Designation

Duchenne Gene Therapy SRP-9001 Wins Priority Review

Lecanemab Represents Promising Therapy for Alzheimer Disease, Posts Positive Phase 3 Secondary Analyses

Donanemab Shows Greater Ability to Clear Amyloid Plaque Than Aducanumab

Episode Breakdown

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jay Alberts, PhD. [LISTEN TIME: 27 minutes]

Episode 78: A Virtual Reality Platform for Parkinson Disease

Adaptive DBS dynamically adjusts stimulation based on patient brain activity, improving therapy customization and motor symptom management in real-time.

Medtronics’ BrainSense Adaptive DBS and Electrode Identifier Gain CE Mark Approval for Parkinson Disease

The newly announced sham surgery-controlled trial will include 102 patients with moderate PD testing several end points, such as change in ON-time without troublesome dyskinesia, over a 78-week period.

Cell Therapy Bemdaneprocel Advances to Phases 3 Registrational Trial in Parkinson Disease

The Delphi-MD platform is designed for nerve stimulation in diagnostic applications, offering clinicians a tool to support objective and personalized treatment approaches in brain health.

FDA Clears QuantalX Neuroscience’s Delphi Stimulator for Direct Brain Health Diagnosis

Since the Syn-One Test only needs a small punch skin biopsy that can be collected in an office setting, the clinical utility can be enhanced to offer more geographically convenient access for patients earlier in the disease.

Syn-One Test Displays Significant Clinical Utility for the Diagnosis of Synucleinopathies

Although the primary goal was not met, prasinezumab demonstrated encouraging effects on secondary and exploratory measures, such as time to worsening motor function, Clinical Global Impression of Change, MDS-UPDRS motor scores.

Parkinson Agent Prasinezumab Misses Primary End Point But Shows Positive Effects in Other Outcomes

Top stories in neurology, neurological disorders

Neurology News Network

Welcome to this special edition of Neurology News Network. I'm Marco Meglio.

 (NCT04994483) showed that treatment with investigational simufilam (Cassava Sciences), a small molecule agent targeting an altered form of filamen A (FLNA), did not meet each of its pre-specified co-primary, secondary, and exploratory biomarker end points in patients with mild-to-moderate Alzheimer disease (AD). As a result of these findings, the company has decided to discontinue its second phase 3 study of simufilam, ReFocus-ALZ (NCT05026177). ReThink-ALZ was a double-blinded study that randomly assigned 804 patients with confirmed mild or moderate AD to either simufilam 100 mg (n = 403) or a matched placebo (n = 401), dosed orally twice daily (BID) for 52 weeks. After 52 weeks of treatment, simufilam failed to distinguish itself from placebo on the primary end points of Alzheimer’s Disease Assessment Scale-Cognitive Subscale 12 and Alzheimer’s Disease Cooperative Study-Activities of Daily Living.

2024 International Congress of Parkinson’s Disease and Movement Disorders (MDS)

, held September 27-October 1, in Philadelphia, Pennsylvania, investigators presented an outline of a 

 evaluating the therapeutic potential of lamotrigine (Lamictal), an FDA-approved antiseizure medication, in patients with dementia with Lewy bodies (DLB). The study, which will enroll 60 patients aged 60 years and older from a hospital in Seoul, Korea, is estimated to be completed in early 2025.In the study, eligible participants will be randomly assigned 1:1 to either standard of care (rivastigmine) plus either oral lamotrigine or matching placebo for a 20-week treatment period. The trial will use change in Clinical Dementia Rating-Sum of Boxes (CDR-SB) as the primary end point, with additional secondary end points that included Mini Mental State Examination, CDR, Caregiver Administered-Neuropsychiatric Inventory, Mayo Fluctuation Scale, and Timed up and Go test, among others.

Recently published data using electronic health records for more than 3 million US veterans revealed that 

hearing loss was an independent risk factor

 for later development of Parkinson disease (PD), even after adjusting for competing risk of death, age, head trauma, frailty, and established prodromal disorders. Investigators concluded that hearing screening and hearing intervention are low-cost, low-risk measures that may influence the later development of synucleinopathy and could be the most important modifiable risk factor for both dementia in midlife and PD.Published in 

, the analysis included electronic health record data from the US Department of Veterans Affairs for veterans who had an audiogram (n = 3,596,365) from January 1999 to December 2022. Of those included, 20.8% (n = 750,010) had normal hearing (<20 dB) at the time of audiometry examination.

For more direct access to expert insight, head to NeurologyLive.com. This has been Neurology News Network. Thanks for watching.

Neurology News Network. for the week ending November 30, 2024. [WATCH TIME: 4 minutes]

Alzheimer Agent Simufilam Fails Phase 3, Lamotrigine Trial in DLB, Hearing Loss Independent Risk Factor for Parkinson

Cerevance’s phase 3 ARISE pivotal trial

Neurology News Network. for the week ending November 23, 2024. [WATCH TIME: 4 minutes]

Parkinson Disease

Latest News